MDVN » Topics » EXHIBIT INDEX

This excerpt taken from the MDVN 8-K filed Dec 17, 2009.

EXHIBIT INDEX

 

99.1    Press Release dated December 17, 2009 entitled “Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization.”
This excerpt taken from the MDVN 8-K filed Nov 4, 2009.

EXHIBIT INDEX

 

99.1   Press release, dated November 4, 2009, entitled “Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update.”
This excerpt taken from the MDVN 8-K filed Nov 3, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated November 3, 2009, entitled “Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer’s Disease.”
This excerpt taken from the MDVN 8-K filed Oct 27, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated October 27, 2009, entitled “Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer.”
This excerpt taken from the MDVN 8-K filed Sep 23, 2009.

EXHIBIT INDEX

 

99.1   Press release, dated September 23, 2009, entitled “Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer.”
This excerpt taken from the MDVN 8-K filed Aug 5, 2009.

EXHIBIT INDEX

 

99.1   Press release, dated August 5, 2009, entitled “Medivation Reports Second Quarter 2009 Financial Results and Provides Corporate Update.”
This excerpt taken from the MDVN 8-K filed Jul 31, 2009.

EXHIBIT INDEX

 

99.1   Press release, dated July 30, 2009, entitled “Pfizer and Medivation Initiate Phase 3 Trial of Dimebon in Patients with Huntington Disease.”
This excerpt taken from the MDVN 8-K filed Jun 11, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated June 11, 2009, entitled “Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 ‘CONNECTION’ Trial of Dimebon in Patients with Alzheimer’s Disease.”
This excerpt taken from the MDVN 8-K filed Jun 2, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated June 2, 2009, entitled “Medivation Announces Positive New Efficacy Data from Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients.”
This excerpt taken from the MDVN 8-K filed May 28, 2009.

EXHIBIT INDEX

 

  1.1

   Underwriting Agreement by and between Medivation, Inc. and J. P. Morgan Securities Inc., as representative of the underwriters, dated May 27, 2009

  5.1

   Opinion of Cooley Godward Kronish LLP

23.1

   Consent of Cooley Godward LLP (reference is made to Exhibit 5.1)

99.1

   Press release, dated May 27, 2009, entitled “Medivation Announces Pricing of Public Offering”

 

This excerpt taken from the MDVN 8-K filed May 27, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated May 26, 2009, entitled “Medivation Announces Offering of 2,750,000 Shares of Common Stock.”
This excerpt taken from the MDVN 8-K filed May 11, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated May 11, 2009, entitled “Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update.”
This excerpt taken from the MDVN 8-K filed Mar 18, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated March 18, 2009, entitled “Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer.”
This excerpt taken from the MDVN 10-K filed Mar 16, 2009.

EXHIBIT INDEX

Unless otherwise indicated below, the Commission file number to the exhibit is No. 001-32836 for filings made in or after March 2006 and No. 000-20837 for filings made prior to March 2006.

 

Exhibit No.

 

Exhibit Description

3.1(a)   Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1(a) to the Quarterly Report on Form 10-QSB of Medivation, Inc. for the quarter ended June 30, 2005).
3.1(b)   Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1(b) to the Quarterly Report on Form 10-QSB of Medivation, Inc. for the quarter ended June 30, 2005).
3.1(c)   Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1(c) to the Quarterly Report on Form 10-QSB of Medivation, Inc. for the quarter ended June 30, 2005).
3.1(d)   Certificate of Designations of the Series B Convertible Preferred Stock of Orion Acquisition Corp. II (incorporated by reference to Exhibit 3.1(d) to the Quarterly Report on Form 10-QSB of Medivation, Inc. for the quarter ended June 30, 2005).
3.1(e)   Certificate of Designations of the Series C Junior Participating Preferred Stock of Medivation, Inc (incorporated by reference to Exhibit 3.1(d) to the Annual Report on Form 10-KSB of Medivation, Inc. for the fiscal year ended December 31, 2007).
3.2   Amended and Restated Bylaws of Medivation, Inc.
4.1   Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-03252)).
4.2   Rights Agreement, dated as of December 4, 2006, between Medivation, Inc. and American Stock Transfer & Trust Company, as Rights Agent, which includes the form of Certificate of Designations of the Series C Junior Participating Preferred Stock of Medivation, Inc. as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on December 4, 2006).
10.1   Registration Rights Agreement by and among Orion Acquisition Corp. II and Special Situations Fund III, L.P., Special Situations Cayman Fund, L.P. and Special Situations Private Equity Fund, L.P., dated as of December 17, 2004 (incorporated by reference to Exhibit 10.3(a) to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-122431)).
10.2(a)   Warrant to purchase Common Stock of Medivation Neurology, Inc. assumed by Orion Acquisition Corp. II issued to Joseph J. Grano, Jr., dated as of June 8, 2004 (incorporated by reference to Exhibit 10.5(a) to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-122431)).
10.2(b)   Warrant to purchase Common Stock of Medivation Neurology, Inc. assumed by Orion Acquisition Corp. II issued to Joseph J. Grano, Jr., dated as of August 1, 2004 (incorporated by reference to Exhibit 10.5(b) to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-122431)).
10.2(c)   Warrant to purchase Common Stock of Medivation Neurology, Inc. assumed by Orion Acquisition Corp. II issued to Joseph J. Grano, Jr., dated as of September 1, 2004 (incorporated by reference to Exhibit 10.5(c) to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-122431)).
10.2(d)   Amendment Agreement by and between Orion Acquisition Corp. II and Joseph J. Grano, Jr., dated as of December 17, 2004 (incorporated by reference to Exhibit 10.5(d) to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-122431)).


Table of Contents

Exhibit No.

 

Exhibit Description

10.3   Warrant to purchase Common Stock of Medivation Neurology, Inc. assumed by Orion Acquisition Corp. II issued to David T. Hung, M.D., dated as of November 16, 2004 (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form SB-2 of Medivation, Inc. (formerly Orion Acquisition Corp. II) (No. 333-122431)).
10.4(a)*   Amended and Restated 2004 Equity Incentive Award Plan (incorporated by reference to Exhibit 10.4(a) to the Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007).
10.4(b)*   Form of Stock Option Agreement (incorporated by reference to Exhibit 10.7(b) to the Annual Report on Form 10-KSB of Medivation, Inc. (formerly Orion Acquisition Corp. II) for the year ended December 31, 2004).
10.4(c)*   Form of Stock Option Agreement (incorporated by reference to Exhibit 10.7(c) to the Annual Report on Form 10-KSB of Medivation, Inc. (formerly Orion Acquisition Corp. II) for the year ended December 31, 2004).
10.5   Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on December 8, 2006).
10.6   Common Stock Purchase Agreement, dated as of September 7, 2007, by and between Medivation, Inc. and Azimuth Opportunity Ltd. (incorporated by reference to Exhibit 10.1 to Medivation, Inc.’s Current Report on Form 8-K filed on September 10, 2007).
10.7   Form of Purchase Agreement, dated as of June 22, 2008, between Medivation, Inc. and the purchasers of its common stock (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 23, 2008).
10.8**   Amended and Restated Collaboration Agreement, dated as of October 20, 2008, between Medivation, Inc. and Pfizer Inc. (incorporated by reference to Exhibit 10.8 to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2008).
10.9*   Bonuses for Fiscal Year 2008 and Base Salaries for Fiscal Year 2009 for Certain Executive Officers (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 5, 2008).
10.10*   Medivation, Inc. 2009 Bonus Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on November 5, 2008).
10.11*  

Change of Control Severance Benefits Agreement, dated as of February 2, 2009, between Medivation, Inc. and David Hung, M.D.

10.12*  

Severance Benefits Agreement, dated as of February 9, 2009, between Medivation, Inc. and Rohan Palekar.

10.13*   Form of Medivation, Inc. Change of Control Severance Benefits Agreement.
16   Letter from SingerLewak LLP to the Securities and Exchange Commission (incorporated by reference to Exhibit 16.1 to the Current Report on Form 8-K filed on March 23, 2007).
21   Subsidiaries of Medivation, Inc.
23.1   Consent of Independent Registered Public Accounting Firm.
23.2   Consent of Former Independent Registered Public Accounting Firm.
24   Power of attorney (contained on signature page).
31.1   Certification pursuant to Rule 13a-14(a)/15d-14(a).
31.2   Certification pursuant to Rule 13a-14(a)/15d-14(a).
32.1   Certifications of Chief Executive Officer and Chief Financial Officer.

 

* Indicates management contract or compensatory plan or arrangement.
** Confidential treatment has been granted with respect to certain portions of this exhibit.
This excerpt taken from the MDVN 8-K filed Mar 16, 2009.

EXHIBIT INDEX

 

99.1    Press release, dated March 16, 2009, entitled “Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update.”
This excerpt taken from the MDVN 8-K filed Feb 25, 2009.

EXHIBIT INDEX

 

99.1   Press release, dated February 25, 2009, entitled “Medivation Announces New Positive Efficacy Data from Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients.”

 

This excerpt taken from the MDVN 8-K filed Dec 17, 2008.

EXHIBIT INDEX

 

99.1    Press release, dated December 17, 2008, entitled “Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients.”

 

This excerpt taken from the MDVN 8-K filed Nov 10, 2008.

EXHIBIT INDEX

 

99.1    Press release, dated November 10, 2008, entitled “Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update.”

 

This excerpt taken from the MDVN 8-K filed Nov 5, 2008.

EXHIBIT INDEX

 

10.1    Bonuses for Fiscal Year 2008 and Base Salaries for Fiscal Year 2009 for Certain Executive Officers.
10.2    Medivation, Inc. 2009 Bonus Plan.
This excerpt taken from the MDVN 8-K filed Oct 22, 2008.

EXHIBIT INDEX

 

99.1    Press release, dated October 22, 2008, entitled “Medivation Announces Presentation of 24-Week Clinical Data Of MDV3100 in Castration-Resistant Prostate Cancer Patients.”
This excerpt taken from the MDVN 8-K filed Sep 3, 2008.

EXHIBIT INDEX

 

99.1    Press release, dated September 3, 2008, entitled “Pfizer and Medivation Enter Into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer’s and Huntington’s Diseases.”
This excerpt taken from the MDVN 8-K filed Aug 11, 2008.

EXHIBIT INDEX

 

99.1    Press release, dated August 11, 2008, entitled “Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update.”
This excerpt taken from the MDVN 8-K filed Jul 30, 2008.

EXHIBIT INDEX

 

99.1    Press release, dated July 30, 2008, entitled “Medivation Presents Positive New Data on Dimebon’s Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimer’s Disease.”
This excerpt taken from the MDVN 8-K filed Jul 18, 2008.

EXHIBIT INDEX

 

99.1   Press release, dated July 17, 2008, entitled “Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer’s Disease.”
This excerpt taken from the MDVN 8-K filed Jul 7, 2008.

EXHIBIT INDEX

 

99.1   Press release, dated July 7, 2008, entitled “Medivation Announces Positive Top-Line Results from Phase 2 Dimebon Study in Huntington’s Disease”
This excerpt taken from the MDVN 8-K filed Jun 23, 2008.

EXHIBIT INDEX

 

  5.1    Opinion of Cooley Godward Kronish LLP
10.1    Form of Purchase Agreement
23.1    Consent of Cooley Godward Kronish LLP (included as part of Exhibit 5.1)
This excerpt taken from the MDVN 8-K filed Sep 10, 2007.

EXHIBIT INDEX

 

10.1 Common Stock Purchase Agreement, dated as of September 7, 2007, by and between Medivation, Inc. and Azimuth Opportunity Ltd.

 

99.1 Press Release of Medivation, Inc., dated September 10, 2007.
This excerpt taken from the MDVN 8-K filed Jun 11, 2007.

Exhibit Index

 

Exhibit No.

  

Description

99.1

   Press Release dated June 11, 2007.
This excerpt taken from the MDVN 8-K filed Mar 23, 2007.

EXHIBIT INDEX

 

16.1   Letter from Singer Lewak Greenbaum & Goldstein LLP to the Securities and Exchange Commission.
This excerpt taken from the MDVN 8-K filed Dec 8, 2006.

EXHIBIT INDEX

 

1.1    Placement Agent Agreement, dated December 7, 2006, between Medivation, Inc. and Cowen and Company, LLC, Leerink Swann & Company, Rodman & Renshaw, LLC and Emerging Growth Equities, Ltd.
10.1    Form of Subscription Agreement.
99.1    Press release dated December 8, 2006.
This excerpt taken from the MDVN 8-K filed Dec 4, 2006.

EXHIBIT INDEX

 

4.1    Rights Agreement, dated as of December 4, 2006, between Medivation, Inc. and American Stock Transfer & Trust Company, as Rights Agent, which includes the form of Certificate of Designations of the Series C Junior Participating Preferred Stock of Medivation, Inc. as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C.
99.1    Text of Press Release dated December 4, 2006.
This excerpt taken from the MDVN 8-K filed May 19, 2006.

EXHIBIT INDEX

 

1.1    Placement Agent Agreement, dated May 15, 2006, between Medivation, Inc. and Emerging Growth Equities, Ltd.
99.1    Press release dated May 16, 2006.
This excerpt taken from the MDVN 8-K filed Oct 11, 2005.

EXHIBIT INDEX

 

Exhibit No.    

 

Description    


99.1   Press Release dated October 11, 2005
99.2   Press Release dated October 11, 2005
This excerpt taken from the MDVN 8-K filed May 20, 2005.

EXHIBIT INDEX

 

Exhibit No.

 

Description    


99.1   Press release dated May 18, 2005.
This excerpt taken from the MDVN 8-K filed May 13, 2005.

EXHIBIT INDEX

 

Exhibit No.

 

Description    


99.1   Press release dated May 12, 2005.
This excerpt taken from the MDVN 8-K filed May 2, 2005.

EXHIBIT INDEX

 

Exhibit No.

 

Description    


99.2   Financial Statements of Medivation, Inc.
This excerpt taken from the MDVN DEFA14A filed May 2, 2005.

EXHIBIT INDEX

 

Exhibit No.

 

Description    


99.2   Financial Statements of Medivation, Inc.
This excerpt taken from the MDVN 8-K filed Mar 4, 2005.

EXHIBIT INDEX

 

Exhibit No.

 

Description    


99.2   Financial Statements of Medivation, Inc.
This excerpt taken from the MDVN DEFA14A filed Mar 4, 2005.

EXHIBIT INDEX

 

Exhibit No.

 

Description    


99.2   Financial Statements of Medivation, Inc.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki